-
公开(公告)号:US07429604B2
公开(公告)日:2008-09-30
申请号:US11151627
申请日:2005-06-13
IPC分类号: A61K31/44 , C07D211/82 , C07D401/02
CPC分类号: C07D401/10 , C07D213/40 , C07D213/55 , C07D213/56 , C07D213/57 , C07D213/61 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/89 , C07D239/26 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14
摘要: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, X1, X2, X3, X4, and X5 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译: 本发明提供式(I)化合物或其立体异构体或药学上可接受的盐或溶剂合物形式,其中变量A,L,Z,X 1,X 2 >,X 3,X 4和X 5如本文所定义。 式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆激肽释放酶。 特别地,它涉及作为选择性因子XIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号:US20120041190A1
公开(公告)日:2012-02-16
申请号:US13024544
申请日:2011-02-10
申请人: James R. Corte , Tianan Fang , Carl P. Decicco , Donald J.P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
发明人: James R. Corte , Tianan Fang , Carl P. Decicco , Donald J.P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC分类号: C07D487/06 , C07D513/06 , C07D498/16
CPC分类号: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
摘要: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译: 本发明提供式(I)的化合物或其立体异构体,互变异构体或其药学上可接受的盐,其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号:US08940720B2
公开(公告)日:2015-01-27
申请号:US13024544
申请日:2011-02-10
申请人: James R. Corte , Tianan Fang , Carl P. Decicco , Donald J. P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
发明人: James R. Corte , Tianan Fang , Carl P. Decicco , Donald J. P. Pinto , Karen A. Rossi , Zilun Hu , Yoon Jeon , Mimi L. Quan , Joanne M. Smallheer , Yufeng Wang , Wu Yang
IPC分类号: C07D487/08 , C07D487/02 , A61K31/33 , A61K31/395 , C07D498/08
CPC分类号: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
摘要: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译: 本发明提供式(I)的化合物或其立体异构体,互变异构体或其药学上可接受的盐,其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号:US20180333395A1
公开(公告)日:2018-11-22
申请号:US16038739
申请日:2018-07-18
申请人: Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
发明人: Peter Tai Wah Cheng , Robert F. Kaltenbach, III , Jun Li , Jun Shi , Yan Shi , Shiwei Tao , Hao Zhang , Suresh Dhanusu , Kumaravel Selvakumar , Ramesh Babu Reddigunta , Steven J. Walker , Lawrence J. Kennedy , James R. Corte , Tianan Fang , Sutjano Jusuf
IPC分类号: A61K31/4192 , C07D249/06 , C07D401/14 , C07D401/04 , A61K31/27 , A61K31/454
摘要: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US20140221338A1
公开(公告)日:2014-08-07
申请号:US14236973
申请日:2012-08-06
申请人: Donald J. P. Pinto , James R. Corte , Paul J. Gilligan , Tianan Fang , Leon M. Smith, II , Yufeng Wang , Wu Yang , William R. Ewing
发明人: Donald J. P. Pinto , James R. Corte , Paul J. Gilligan , Tianan Fang , Leon M. Smith, II , Yufeng Wang , Wu Yang , William R. Ewing
IPC分类号: C07D471/06 , C07D498/06 , C07D487/06
CPC分类号: C07D519/00 , C07D471/06 , C07D471/08 , C07D487/06 , C07D487/08 , C07D498/06 , C07D498/08
摘要: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译: 本发明提供式(Ia)化合物或其立体异构体,互变异构体或其药学上可接受的盐,其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号:US09221818B2
公开(公告)日:2015-12-29
申请号:US14236973
申请日:2012-08-06
申请人: Donald J. P. Pinto , James R. Corte , Paul J. Gilligan , Tianan Fang , Leon M. Smith, II , Yufeng Wang , Wu Yang , William R. Ewing
发明人: Donald J. P. Pinto , James R. Corte , Paul J. Gilligan , Tianan Fang , Leon M. Smith, II , Yufeng Wang , Wu Yang , William R. Ewing
IPC分类号: C07D487/08 , C07D471/06 , C07D487/06 , C07D498/06
CPC分类号: C07D519/00 , C07D471/06 , C07D471/08 , C07D487/06 , C07D487/08 , C07D498/06 , C07D498/08
摘要: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译: 本发明提供式(Ia)化合物或其立体异构体,互变异构体或其药学上可接受的盐,其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号:US20060009455A1
公开(公告)日:2006-01-12
申请号:US11151627
申请日:2005-06-13
申请人: James Corte , Jon Hangeland , Miml Quan , Joanne Smallheer , Tianan Fang
发明人: James Corte , Jon Hangeland , Miml Quan , Joanne Smallheer , Tianan Fang
IPC分类号: A61K31/513 , A61K31/498 , A61K31/4709 , C07D43/02 , C07D45/02
CPC分类号: C07D401/10 , C07D213/40 , C07D213/55 , C07D213/56 , C07D213/57 , C07D213/61 , C07D213/64 , C07D213/73 , C07D213/74 , C07D213/89 , C07D239/26 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/14
摘要: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, X1, X2, X3, X4, and X5 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
摘要翻译: 本发明提供式(I)化合物或其立体异构体或药学上可接受的盐或溶剂合物形式,其中变量A,L,Z,X 1,X 2 >,X 3,X 4和X 5如本文所定义。 式(I)的化合物可用作凝血级联和/或接触激活系统的丝氨酸蛋白酶的选择性抑制剂; 例如凝血酶,因子Xa,因子XIa,因子IXa,因子VIIa和/或血浆激肽释放酶。 特别地,它涉及作为选择性因子XIa抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
-
-
-
-
-